InvestorsHub Logo
Followers 32
Posts 4083
Boards Moderated 1
Alias Born 06/08/2003

Re: None

Monday, 05/21/2012 11:13:20 AM

Monday, May 21, 2012 11:13:20 AM

Post# of 67
Novartis has a co-promotion agreement with Eisai and Co. Ltd (ESALY) in Japan.

Switzerland-based pharmaceutical company, Novartis AG (NVS - Snapshot Report) recently announced positive phase III data from the GLOW 2 study of its pipeline candidate NVA237. The candidate is being studied for the treatment of chronic obstructive pulmonary disease (COPD). The study showed rapid improvement in lung function and symptom relief over one year in COPD patients.

http://www.zacks.com/stock/news/75514/novartis-progresses-with-nva237

I am only expressing my personal opinions or repeating public information from SEC filings or media outlets-which may or may not be correct. Do your own investigating before investing!